The Federal Trade Commission (FTC) said it has approved Cardinal Health's application to sell nuclear pharmacy assets to Patient Care Infusion (PCI).
The sale of the assets was required under a 2011 settlement with the FTC, which resolved charges that Cardinal's acquisition of three nuclear pharmacies from Biotech was anticompetitive. After Cardinal had completed that acquisition, it closed its own competing nuclear pharmacies in Las Vegas; Albuquerque, NM; and El Paso, TX. The 2011 FTC order required Cardinal to reconstitute and sell nuclear pharmacies in each of the cities to an FTC-approved buyer.
These assets have been reconstituted in conjunction with PCI, which has the capacity and ability to operate the new nuclear pharmacies in a competitive manner, according to the FTC.
